Navigation Links
Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Unilife Medical Solutions Limited
Date:1/7/2009

NEW YORK, Jan. 7 /PRNewswire/ -- Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview(R) (EIO(R)) on Unilife Medical Solutions Limited (UNI-ASX). The full 72-page report can be found at www.crystalra.com and www.unilife.com.

Unilife Medical Solutions Limited ("Unilife" or "the Company") develops and supplies innovative safety medical devices to healthcare and pharmaceutical markets. Specifically, the Company is focused on targeting pharmaceutical markets for prefilled safety syringes; healthcare markets that mandate the use of sharps safety devices to prevent needlestick injuries; and the U.S. medical device contract manufacturing market. Unilife has developed a patent-protected portfolio of safety syringes, with product lines including the Unilife Ready-to-Fill Syringe ([RTFS] hereafter referred to as the Unilife Prefilled Syringe), the Unitract(TM) 1mL Insulin and Safe Syringes, and the Unitract(TM) Clinical Range.

The key distinctive feature in all of Unilife's safety syringes is that the operator may control the speed of automatic needle retraction within a fully integrated safety syringe. This novel combination of safety features, which Unilife does not believe is available with any other technology on the market today, can virtually eliminate the risk of acquiring bloodborne infections, such as the human immunodeficiency virus (HIV) or hepatitis C, via needlestick injuries or aerosol (blood splatter).

In July 2008, sanofi-aventis SA (SNY-NYSE) -- the world's fourth largest pharmaceutical group and largest purchaser of prefilled syringes -- signed an Exclusive Agreement with Unilife, under which sanofi-aventis paid $13.9 million (euro 10 million) for the right to purchase the Unilife Prefilled Syringe for five years. Sanofi-aventis is also financing Unilife's three-year industrialization program for the Unilife Prefilled Syringe, which could have a total value of up to $23.6 million (euro 17 million). The Company believes that this alliance validates the strength of its proprietary technology and its competency in the development and operation of automated assembly systems. Upon the expected signing of two additional agreements with sanofi-aventis in the next 18 months, Unilife maintains a solid cash position and projects profitable operations moving forward.

About Crystal Research Associates, LLC

Crystal Research Associates, LLC is an independent research firm that provides institutional-quality, fee-based research to small and mid-cap companies. Crystal Research Associates' unique and novel product, the Executive Informational Overview(R) (EIO(R)), is free of investment ratings, target prices, and forward-looking financial models. The EIO(R) presents a crystal clear, detailed report on a company (public or private) in a manner that is easily understood by the Wall Street financial community. The EIO(R) details a company's product/technology/service offerings, market size(s), key intellectual property, leadership, growth strategy, competition, risks, financial statements, key events, and other such fundamental information. Crystal Research Associates has offices in New York City, Delray Beach, Montreal, and Toronto. Crystal Research Associates has been compensated by the Company in cash of forty-two thousand five hundred U.S. dollars and five hundred thousand Options/Warrants to purchase Unilife stock for its services in creating this report, for updates, and for printing costs.

Forward-Looking Safe Harbor Statement

Statements in this news release regarding future financial and operating results, potential applications of the Company's technology, opportunities for the Company, and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements including, limited operating history, need for future capital, and economic conditions generally. Additional information on potential factors that could affect results and other risks and uncertainties are detailed from time to time in the Company's periodic reports, including forms filed with the Australian Securities Exchange (ASX).

These statements, and other forward-looking statements, are not guarantees of future performance and involve risks and uncertainties. Crystal Research Associates assumes no obligation to update any of the forward-looking statements in this release.


'/>"/>
SOURCE Crystal Research Associates, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Crystallography reveals the 3-D structure of mammalian sperm receptor
2. Asia Wellness Cruise Offers Crystal Guests Peace of Mind, Body & Spirit
3. Crystalens HD(TM) Receives FDA Approval
4. Success for Crystal Meth Drug Addict on YouTube
5. Steve and Paula Mae Schwartz Honored With Publicity Club of New Englands Crystal Bell Award
6. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on BioCurex, Inc.
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Advaxis, Inc.
8. Measurement technique probes surface structure of gold nanocrystals
9. Crystal Light and Mandy Moore Launch Unique Online Wellness Community for Women
10. Wellness Experts From Cleveland Clinic Set for 2008 Crystal Voyages
11. A New Year, A New Opportunity: Metropolitan Community Church Leaders Urge Faith Leaders to Address HIV and Crystal Meth Use Among LGBT Youth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... “A Prophets Bones”: a thrilling adventure that reveals the mystery of ... were things that his parents and teachers had asked of him that he had neglected ... going to defy the Almighty Creator. There were some who would have felt themselves to ...
(Date:3/27/2017)... ... ... New patients who have sleep apnea in Aurora, CO, can ... referral. Sleep apnea is often left untreated because patients are not familiar with common ... , Dr. Braasch seeks to raise awareness of sleep apnea in Aurora, CO, ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... custom smile makeovers without requiring a referral. Trimble Dental offers a ... treatment, cosmetic dentistry and dental implants. Whether patients have discolored, crooked or missing ...
(Date:3/27/2017)... ... March 27, 2017 , ... Drs. Justin Kolnick, Kara Diamond, Randall Barton, ... patients about the key role this treatment plays in protecting oral health, along with ... better serve those who need a root canal in White Plains, NY or their ...
(Date:3/27/2017)... ... March 27, 2017 , ... This is the ... popHealth Community in 2014. It is the culmination of collaborative efforts by ... Project Group. OSEHRA Organizational Member Zato Health co-funded the ONC certification and provided ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... , March 27, 2017  Cryoport, Inc. (NASDAQ: ... it intends to offer shares of common stock in ... statement on file with the Securities and Exchange Commission ... other conditions, and there can be no assurance as ... or as to the actual size or terms of ...
(Date:3/27/2017)... , March 27, 2017  Sanderling Ventures, portfolio ... Ethicon, a division of Johnson & Johnson. Torax manufactures ... the treatment of gastro-esophageal reflux disease (GERD). The ... (MSA) technology and the procedure is currently available ... Torax Medical was founded by Sanderling Ventures, ...
(Date:3/27/2017)... 2017 FinancialBuzz.com News Commentary  ... According to a new report by Arcview Market Research, ... grew 34 percent to $6.7 billion and can be expected to grow ... next five years, from $6.7 billion in 2016, to $22.6 billion in ... able to purchase cannabis without a doctor,s recommendation. Voters in ...
Breaking Medicine Technology: